---
layout: post
title: New Drug Approvals 2014 - Pt. III - Droxidopa (Northera ™)
date: '2014-03-20T04:50:00.000Z'
author: Gerard JP van Westen
tags:
- Oral Drugs
- Small Molecule Drugs
- Black Box Warning Drugs
- 2014 New Drugs
modified_time: '2014-03-20T04:50:08.679Z'
thumbnail: http://2.bp.blogspot.com/-eI6XEkVuMWg/Uyhp9ANpSDI/AAAAAAAAPfw/zsKdYDTIWIg/s72-c/northera.jpeg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-4383819929015263987
blogger_orig_url: http://chembl.blogspot.com/2014/03/new-drug-approvals-2014-pt-iii.html
---

<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-eI6XEkVuMWg/Uyhp9ANpSDI/AAAAAAAAPfw/zsKdYDTIWIg/s1600/northera.jpeg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://2.bp.blogspot.com/-eI6XEkVuMWg/Uyhp9ANpSDI/AAAAAAAAPfw/zsKdYDTIWIg/s1600/northera.jpeg" height="156" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,0,1,0,1,0,0,1,1" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="41" src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,0,1,0,1,0,0,1,1" width="400" /></a></div>
<div style="text-align: center;">
<b><br />
</b><b>ATC Code:&nbsp;</b>Unavailable</div>
<div style="text-align: center;">
<b>Wikipedia:</b>&nbsp;<a href="https://en.wikipedia.org/wiki/Droxidopa">Droxidopa</a></div>
<div style="text-align: center;">
<b>ChEMBL:&nbsp;</b><span style="text-align: left;"><a href="https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103827">CHEMBL2103827</a></span></div>
<br />
<div>
On February 18th the&nbsp;<a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm386311.htm">FDA approved</a>&nbsp;Droxidopa (tarde name Northera™)&nbsp;for the treatment of neurogenic orthostatic hypotension (NOH). NOH is a rare, chronic and often debilitating drop in blood pressure upon standing, and is associated with Parkinson's disease, multiple-system atrophy, and pure autonomic failure. Symptoms of NOH include dizziness, light-headedness, blurred vision, fatigue and fainting when a person stands.&nbsp;</div>
<div>
<br /></div>
<div>
<b>Target(s)</b><br />
Droxidopa (also known as L-DOPS, L-threo-dihydroxyphenylserine, and SM-5688) is a prodrug which can be <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3466.2006.00189.x/abstract">converted</a> to norepinephrine (noradrenaline) by&nbsp;<a href="https://en.wikipedia.org/wiki/Aromatic_L-amino_acid_decarboxylase">Aromatic L-amino acid decarboxylase</a>&nbsp;(<a href="http://www.uniprot.org/uniprot/P20711">Uniprot P20711</a>&nbsp;;&nbsp;<a href="https://www.blogger.com/(http://enzyme.expasy.org/EC/4.1.1.28">EC 4.1.1.28</a>). Norepinephrine in turn can be converted to epinephrine by&nbsp;<a href="https://en.wikipedia.org/wiki/Phenylethanolamine_N-methyltransferase">Phenylethanolamine N-methyltransferase</a>&nbsp;( <a href="http://www.uniprot.org/uniprot/P11086">Uniprot P11086&nbsp;</a>). Droxidopa<a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3466.2006.00189.x/abstract"> can cross the blood</a> brain barrier, contrary to epinephrine and&nbsp;norepinephrine.&nbsp;&nbsp;<a href="http://link.springer.com/article/10.1007%2Fs10286-007-1004-0">Patients with NOH</a> suffer from depleted levels of epinephrine and&nbsp;norepinephrine. Droxidopa increases the levels of both in the peripheral nervous system and leads to an increased heart rate and blood pressure.<br />
<i><br />
</i></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-zMlQsnhc-9g/UyhjU3Lp-1I/AAAAAAAAPfg/vD4SmHqcg7g/s1600/CHEMBL2103827.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://3.bp.blogspot.com/-zMlQsnhc-9g/UyhjU3Lp-1I/AAAAAAAAPfg/vD4SmHqcg7g/s1600/CHEMBL2103827.png" height="320" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<span style="text-align: left;">Droxidopa (</span><a href="https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL2103827" style="text-align: left;">CHEMBL2103827</a>;&nbsp;<span style="text-align: left;">Pubchem :&nbsp;<a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=92974">92974</a></span><span style="text-align: left;">&nbsp;) is a small molecule drug with a molecular weight of 213.2 Da, an AlogP of -2.92, 3 rotatable bonds, and no rule of 5 violations.</span></div>
<div>
<b><br />
</b></div>
<div>
<b>Canonical SMILES</b>&nbsp;: N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(=O)O</div>
<b>InChi</b>: InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1<br />
<div>
<br /></div>
<div>
<b><br />
</b><b>Dosage</b></div>
Droxidopa starting dose is 100mg three times daily (which can be titrated to a maximum of 600 mg three times daily). One dose should be taken in late afternoon at least 3 hours prior to bedtime to reduce the potential for supine hypertension during sleep.<br />
<div>
<br /></div>
<div>
<b>Warnings</b><br />
Neuroleptic malignant syndrome (NMS) has been reported with&nbsp;Droxidopa&nbsp;use during post-marketing surveillance in Japan. NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.<br />
<br />
Ischemic Heart Disease, Arrhythmias, and Congestive Heart Failure<br />
Droxidopa may exacerbate existing ischemic heart disease, arrhythmias and congestive heart failure.<br />
<br />
<b>Pharmacokinetics</b><br />
Absorption<br />
Cmax of droxidopa were reached by 1 - 4 hours post-dose in healthy volunteers. High-fat meals have a moderate impact on droxidopa exposure with Cmax and AUC decreasing by 35% and 20% respectively, and delaying Cmax by approximately 2 hours.<br />
<br />
Distribution<br />
Droxidopa exhibits plasma protein binding of 75% at 100 ng/mL and 26% at 10,000 ng/mL with an apparent volume of distribution of about 200 L.<br />
<br />
Metabolism<br />
The metabolism of droxidopa is mediated by catecholamine pathway and not through the cytochrome P450 system. Plasma norepinephrine levels peak within 3 to 4 hours (generally &lt; 1 ng/mL) and variable with no consistent relationship with dose. The contribution of the metabolites of droxidopa other than norepinephrine to its pharmacological effects is not well understood.<br />
<br />
Elimination<br />
The mean elimination half-life of droxidopa is 2.5 hours. The major route of elimination of droxidopa and its metabolites is via the kidneys.<br />
<br />
<b>Drug Interactions</b>&nbsp;</div>
<div>
No dedicated drug-drug interaction studies were performed for droxidopa. Carbidopa, a peripheral dopa-decarboxylase inhibitor, could prevent the conversion of&nbsp;droxidopa&nbsp;to norepinephrine outside of the central&nbsp;nervous system (CNS).<br />
<br />
L-DOPA/dopa-decarboxylase inhibitor combination drugs decreased clearance of&nbsp;droxidopa, increased AUC to droxidopa approximately 100%, and increased exposure to 3-OM-DOPS of approximately 50%. However, it was found that the decreased clearance was not associated with a significant need for a different treatment dose or increases in associated adverse events.<br />
<br />
Dopamine agonists, amantadine derivatives, and MAO-B inhibitors do not appear to effect&nbsp;droxidopa&nbsp;clearance, no dose adjustments are required.&nbsp;</div>
<div>
<br /></div>
<b>Pregnancy</b><br />
Droxidopa is classified as&nbsp;<a href="http://en.wikipedia.org/wiki/Pregnancy_category">pregnancy category C</a>. There are no adequate and well controlled trials in pregnant women.<br />
<i><br />
</i>The license holder is <a href="http://chelseatherapeutics.com/">Chelsea Therapeutics</a>, the prescribing information can be found&nbsp;<a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203202lbl.pdf">here</a>.</div>
